Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector

Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term.

On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s MedTech “looks well-positioned on several fronts.” The firm also thinks that major product cycles, healthier hospital spending, and valuations near their lows all signal a supportive setup for the industry in the year ahead.

In its earnings for fiscal Q4 2025, Becton, Dickinson and Company (NYSE:BDX) announced that the merger of its Biosciences and Diagnostic Solutions, which the company separated and refers to as New BD, with Waters Corporation will be completed around the end of the first quarter of 2026. New BD will be a MedTech company with far-reaching influence on patients and healthcare worldwide. In FY25, New BD reported revenue of $17.5 billion, compared with $16.8 billion in the prior-year period.

Becton, Dickinson and Company (NYSE:BDX)’s overall revenues for Q4 were $5.9 billion, which showed an 8.3% growth YoY. The company’s cash and cash equivalents at the end came in at $641 million, and operating cash flow was $3.4 billion in 2025. Becton returned $2.2 billion to investors in dividends and share repurchases, exhibiting its commitment to returning value to shareholders.

Becton, Dickinson and Company (NYSE:BDX) is an American multinational medical technology company that manufactures and sells essential medical devices and related products.

While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 11 Worst Performing Dividend Stocks Year-to-Date.

Disclosure: None.